

Thrombotic Risk Assessment Genotyping Temporarily Unavailable

Effective Date: July 20, 2020

We were informed last week that Hologic, the manufacturer of our Thrombotic Risk Assessment (TRA) genotyping assays, have temporarily suspended production of these reagents to focus on COVID-19 tests. Orders for the three tests listed below will continue to be performed in-house for as long as our current reagent stocks allow. Once depleted, the lab will continue to accept orders, genomic DNA will be extracted and stored until the test is available. We anticipate delays of approximately one month and will begin as early as this week.

Affected tests include:

- Factor V Genotyping Analysis
 - EPIC Code: LAB6383
 - SOFT Code: GFVG
 - CPT Code: 81241

- Prothrombin Genotyping for Thrombotic Risk Assessment
 - EPIC Code: LAB6389
 - SOFT Code: GPROG
 - CPT Code: 81240

- Hyperhomocysteinemia Genotyping for Thrombotic Risk Assessment
 - EPIC Code: LAB6386
 - SOFT Code: MTHG
 - CPT Code: 81291

If you have questions, please contact Client Services (1-800-551-0488, option 5).

Laboratory Test Directory: <http://beaumontlaboratory.com/test-lab-directory>.

Date submitted: July 15, 2020

Submitted by: John Schwartz, M.D., Medical Director, Molecular Pathology
Kausar Jabbar, MD., Medical Director, Molecular Pathology
Susan Daraiseh, PhD., Technical Director, Molecular Pathology

Beaumont Laboratory
Customer Service
1-800-551-0488